TenX Biopharma negotiated a deal with $4.5 million up front for exclusive, worldwide rights to develop and commercialize Genmab’s Phase III T-cell lymphoma candidate, HuMax-CD4®. Genmab will receive undisclosed milestone payments and future sales royalties.
Zanolimumab is a fully human monoclonal anti-CD4 antibody. It is in Phase III development in the U.S. and Europe for the treatment of cutaneous T-cell lymphoma (CTCL) patients and in Phase II trials in Europe and the U.S. for peripheral T-cell lymphoma (PTCL).
In January Genmab’s lead product, Arzerra, received a positive opinion from the European regulatory authorities’ Committee for Medicinal Products for Human Use for the treatment of chronic lymphocytic leukaemia (CLL) in patients who are refractory to fludarabine and alemtuzumab. The antibody was granted accelerated approval by the FDA for this indication in October 2009.
Arzerra is fully human antibody targeting the CD20 molecule in the cell membrane of B cells. In development worldwide in collaboration with GlaxoSmithKline, the antibody is also in mid- and late-stage clinical trials for a range of lymphocytic and B-cell lymphoma indications as well as for the treatment of relapsing remitting multiple sclerosis and rheumatoid arthritis.
Additional antibody-based products in the Genmab clinical pipeline include the head and neck cancer candidate HuMax-EGFr and the multiple myeloma treatment HuMax-CD38. RG1512 is a fully human antibody, developed through a partnership with Roche, that is in a Phase I peripheral vascular disease trial. RG4930, another a fully human antibody developed through the Roche partnership, is currently in Phase I trials by Roche and Genentech for the treatment of asthma.
Genmab’s preclinical pipeline includes HuMax-CD32b, a fully human IgG1,k antibody targeting the CD32b receptor, and HuMax-TF, a fully human antibody targeting human tissue factor.